交易 Inovio Pharmaceuticals, Inc. - INO CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
交易條件
价差 | 0.0500 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 0.001 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Inovio Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Mar 28, 2024 | 13.8400 | 0.7800 | 5.97% | 13.0600 | 14.6400 | 13.0000 |
Mar 27, 2024 | 12.9800 | 0.5700 | 4.59% | 12.4100 | 13.1100 | 12.2900 |
Mar 26, 2024 | 12.3400 | -0.1600 | -1.28% | 12.5000 | 13.2900 | 12.2900 |
Mar 25, 2024 | 12.3400 | 0.5300 | 4.49% | 11.8100 | 12.6900 | 11.7000 |
Mar 22, 2024 | 11.5600 | 0.7300 | 6.74% | 10.8300 | 12.1500 | 10.7800 |
Mar 21, 2024 | 10.9400 | 0.1100 | 1.02% | 10.8300 | 11.3600 | 10.7300 |
Mar 20, 2024 | 10.7600 | 0.2500 | 2.38% | 10.5100 | 10.9200 | 10.2100 |
Mar 19, 2024 | 10.6400 | -0.0100 | -0.09% | 10.6500 | 10.9500 | 10.4500 |
Mar 18, 2024 | 10.6800 | 0.1200 | 1.14% | 10.5600 | 11.1400 | 10.0900 |
Mar 15, 2024 | 10.7100 | -0.0300 | -0.28% | 10.7400 | 11.2500 | 10.5900 |
Mar 14, 2024 | 10.7900 | -0.3100 | -2.79% | 11.1000 | 11.1000 | 10.4200 |
Mar 13, 2024 | 11.2100 | -0.3600 | -3.11% | 11.5700 | 12.5800 | 10.8800 |
Mar 12, 2024 | 11.4900 | -0.2000 | -1.71% | 11.6900 | 12.0050 | 10.8800 |
Mar 11, 2024 | 11.9900 | 1.9100 | 18.95% | 10.0800 | 12.7500 | 10.0800 |
Mar 8, 2024 | 10.1550 | 1.2250 | 13.72% | 8.9300 | 10.7100 | 8.9300 |
Mar 7, 2024 | 9.0000 | -0.6400 | -6.64% | 9.6400 | 9.6500 | 8.3400 |
Mar 6, 2024 | 9.8300 | 0.0600 | 0.61% | 9.7700 | 10.2600 | 9.6100 |
Mar 5, 2024 | 9.6400 | 0.1400 | 1.47% | 9.5000 | 9.7750 | 9.2900 |
Mar 4, 2024 | 9.7600 | 0.1800 | 1.88% | 9.5800 | 9.9600 | 9.1900 |
Mar 1, 2024 | 9.5200 | 0.6700 | 7.57% | 8.8500 | 9.7200 | 8.7400 |
Inovio Pharmaceuticals, Inc. Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Tuesday, April 2, 2024 | ||
时间(协调世界时) (UTC) 14:00 | 国家 US
| 事件 Inovio Pharmaceuticals Inc at Citizens JMP Novel Therapeutics Forum Inovio Pharmaceuticals Inc at Citizens JMP Novel Therapeutics ForumForecast(预报) -上一页 - |
Wednesday, May 8, 2024 | ||
时间(协调世界时) (UTC) 20:00 | 国家 US
| 事件 Q1 2024 Inovio Pharmaceuticals Inc Earnings Release Q1 2024 Inovio Pharmaceuticals Inc Earnings ReleaseForecast(预报) -上一页 - |
Wednesday, May 15, 2024 | ||
时间(协调世界时) (UTC) 13:00 | 国家 US
| 事件 Inovio Pharmaceuticals Inc Annual Shareholders Meeting Inovio Pharmaceuticals Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 10.2623 | 1.77476 | 7.41122 | 4.11193 | 30.4819 |
收入 | 10.2623 | 1.77476 | 7.41122 | 4.11193 | 30.4819 |
總營業費用 | 277.836 | 302.993 | 126.787 | 115.22 | 124.573 |
銷售/一般/行政費用,總計 | 90.1853 | 53.7523 | 37.2478 | 27.2032 | 29.3152 |
研究與開發 | 187.65 | 249.24 | 94.2454 | 88.0173 | 95.2579 |
異常費用(收入) | 0 | 0 | -4.70606 | 0 | 0 |
營業收入 | -267.574 | -301.218 | -119.376 | -111.109 | -94.0911 |
利息收入(費用),非經營淨值 | -6.21775 | -2.34978 | -42.8094 | -10.1968 | -0.70688 |
稅前淨收入 | -277.653 | -303.224 | -162.89 | -120.809 | -94.798 |
稅後淨收入 | -277.653 | -303.224 | -162.89 | -120.552 | -96.9678 |
少數股東權益 | 0 | 0 | 1.06376 | 1.19256 | |
未計算非常項目前的淨收益 | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
淨收入 | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
普通股股東可獲收益 (不含非經常性項目) | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
普通股股東可獲收益 (含非經常性項目) | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
攤薄淨收入 | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
攤薄後加權平均股 | 238.622 | 208.83 | 155.127 | 98.718 | 92.54 |
扣除特別項目的每股攤薄盈利 | -1.17264 | -1.4541 | -1.07274 | -1.20909 | -1.04785 |
每股正常攤薄盈利 | -1.17264 | -1.4541 | -1.10308 | -1.20909 | -1.04785 |
非常規項目總計 | |||||
其他,淨值 | -3.86158 | 0.34337 | -0.7049 | 0.4962 | |
Equity In Affiliates | -2.16521 | -0.43439 | -4.58461 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0.22597 | 0.11494 | 0.12467 | 9.15413 | 0.7844 |
收入 | 0.22597 | 0.11494 | 0.12467 | 9.15413 | 0.7844 |
總營業費用 | 37.2671 | 44.0671 | 56.0708 | 44.9112 | 104.922 |
銷售/一般/行政費用,總計 | 13.5231 | 13.8906 | 13.9509 | 11.824 | 48.4568 |
研究與開發 | 21.744 | 30.1765 | 42.1199 | 33.0871 | 56.4649 |
營業收入 | -37.0411 | -43.9522 | -55.9462 | -35.757 | -104.137 |
利息收入(費用),非經營淨值 | 2.93443 | 5.72854 | 4.2473 | -1.08608 | -4.35694 |
其他,淨值 | -1.42787 | -2.42568 | -2.76429 | -0.94078 | -0.00305 |
稅前淨收入 | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
稅後淨收入 | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
少數股東權益 | 0 | ||||
Equity In Affiliates | 0 | 0 | 0 | 0 | 0 |
未計算非常項目前的淨收益 | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
淨收入 | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
普通股股東可獲收益 (不含非經常性項目) | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
普通股股東可獲收益 (含非經常性項目) | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
攤薄淨收入 | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
攤薄後加權平均股 | 264.354 | 258.438 | 250.585 | 249.351 | 235.278 |
扣除特別項目的每股攤薄盈利 | -0.13442 | -0.15729 | -0.21734 | -0.15153 | -0.46114 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.12685 | -0.15729 | -0.21734 | -0.15153 | -0.46114 |
異常費用(收入) | 2 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 315.243 | 448.445 | 471.171 | 94.201 | 87.8148 |
現金和短期投資 | 252.999 | 401.315 | 411.643 | 89.5341 | 81.2325 |
現金等價物 | 46.3294 | 71.1438 | 250.728 | 22.1961 | 23.6936 |
短期投資 | 206.669 | 330.171 | 160.915 | 67.338 | 57.5388 |
應收賬款總額,淨額 | 11.7382 | 8.03204 | 19.0637 | 2.03212 | 4.05494 |
應收賬款 - 貿易,淨額 | 1.70173 | 5.46685 | 18.56 | 0.70007 | 3.31636 |
預付的費用 | 50.5057 | 39.0982 | 40.4639 | 2.63474 | 2.5274 |
總資産 | 348.533 | 495.941 | 539.772 | 143.952 | 131.113 |
物業/廠房/設備,總計 - 淨額 | 17.9562 | 29.0242 | 24.0894 | 26.556 | 15.949 |
物業/廠房/設備,總計 - 總額 | 39.5196 | 47.9686 | 40.083 | 39.7225 | 25.9489 |
累計折舊,總計 | -21.5634 | -18.9444 | -15.9936 | -13.1665 | -9.99992 |
商譽,淨額 | 10.5134 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
無形資産,淨額 | 2.12986 | 2.62636 | 3.14677 | 3.69385 | 4.76015 |
長期投資 | 2.00714 | 3.9068 | 4.89475 | 6.31536 | 9.40591 |
其他長期資産,總計 | 0.68404 | 1.42579 | 25.9575 | 2.67202 | 2.67 |
流動負債總額 | 96.8681 | 65.7416 | 41.706 | 31.9893 | 35.2998 |
應付賬款 | 19.8625 | 24.2137 | 0.82552 | 6.91908 | 10.0438 |
Payable/Accrued | 45.2204 | 0.54803 | 0.64297 | 0.72973 | 4.60189 |
預提費用 | 29.2224 | 36.3611 | 32.658 | 17.4428 | 15.1386 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 2.5627 | 4.61885 | 7.57944 | 6.89777 | 5.51547 |
負債總額 | 126.171 | 96.2721 | 78.6317 | 140.516 | 44.1771 |
長期債務總額 | 16.6148 | 14.9597 | 18.6558 | 77.0229 | 0 |
遞延所得稅 | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.02477 |
少數股權 | 0 | 1.96976 | 0.09627 | ||
其他負債,總計 | 12.6556 | 15.5387 | 18.2379 | 29.5025 | 8.75633 |
總權益 | 222.363 | 399.669 | 461.141 | 3.4351 | 86.9361 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.25309 | 0.21738 | 0.18685 | 0.10136 | 0.09723 |
額外實收資本 | 1710.66 | 1609.59 | 1367.41 | 742.647 | 707.794 |
留存收益(累計赤字) | -1487.85 | -1209.86 | -906.197 | -739.786 | -620.426 |
其他權益,總計 | -0.69874 | -0.28224 | -0.25615 | 0.47261 | -0.52887 |
總負債和股東權益 | 348.533 | 495.941 | 539.772 | 143.952 | 131.113 |
已發行普通股總數 | 253.091 | 217.383 | 186.851 | 101.361 | 97.2258 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00002 | 0.00002 |
長期債務 | 16.6148 | 14.9597 | 18.6558 | 77.0229 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 174.767 | 203.284 | 233.896 | 315.243 | 350.208 |
現金和短期投資 | 167.473 | 194.925 | 223.751 | 252.999 | 281.883 |
現金等價物 | 18.8046 | 52.7125 | 28.2381 | 46.3294 | 21.9882 |
短期投資 | 148.669 | 142.213 | 195.513 | 206.669 | 259.895 |
應收賬款總額,淨額 | 2.14393 | 5.11623 | 5.03511 | 11.7382 | 10.0807 |
應收賬款 - 貿易,淨額 | 0 | 0.00595 | 0.0733 | 1.70173 | 2.44287 |
預付的費用 | 5.1498 | 3.24281 | 5.11017 | 50.5057 | 58.2442 |
總資産 | 193.097 | 233.038 | 266.583 | 348.533 | 391.968 |
物業/廠房/設備,總計 - 淨額 | 14.7298 | 15.7927 | 16.8489 | 17.9562 | 26.1652 |
商譽,淨額 | 0 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
無形資産,淨額 | 0 | 0 | 2.04778 | 2.12986 | 2.24944 |
長期投資 | 2.9949 | 2.78053 | 2.62378 | 2.00714 | 2.12999 |
其他長期資産,總計 | 0.60532 | 0.66689 | 0.65252 | 0.68404 | 0.70199 |
流動負債總額 | 43.711 | 51.9323 | 55.1511 | 96.8681 | 94.9147 |
Payable/Accrued | 0.71172 | 1.68638 | 1.41727 | 80.9073 | 75.7816 |
預提費用 | 19.4909 | 21.1189 | 21.9336 | 13.3981 | 16.3067 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 3.82808 | 3.74862 | 4.211 | 2.5627 | 2.82645 |
負債總額 | 54.9375 | 63.6664 | 67.369 | 126.171 | 125.271 |
長期債務總額 | 0 | 0 | 0 | 16.6148 | 16.3013 |
長期債務 | 0 | 0 | 0 | 16.6148 | 16.3013 |
遞延所得稅 | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.03205 |
其他負債,總計 | 11.1944 | 11.702 | 12.1859 | 12.6556 | 14.0227 |
總權益 | 138.16 | 169.372 | 199.214 | 222.363 | 266.697 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.26973 | 0.26807 | 0.26274 | 0.25309 | 0.24948 |
額外實收資本 | 1736.6 | 1733.83 | 1728.03 | 1710.66 | 1700.72 |
留存收益(累計赤字) | -1597.96 | -1564.03 | -1528.5 | -1487.85 | -1433.38 |
其他權益,總計 | -0.75107 | -0.69126 | -0.5828 | -0.69874 | -0.88521 |
總負債和股東權益 | 193.097 | 233.038 | 266.583 | 348.533 | 391.968 |
已發行普通股總數 | 269.731 | 268.073 | 262.739 | 253.091 | 249.485 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 |
應付賬款 | 3.19205 | 8.67007 | 11.1944 | ||
長期債務的當前部分/資本租賃 | 16.4883 | 16.7083 | 16.3948 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -279.818 | -303.659 | -167.475 | -120.552 | -96.9678 |
经营活动产生的现金 | -216.215 | -215.709 | -177.979 | -97.8501 | -73.5502 |
经营活动产生的现金 | 3.65671 | 3.0401 | 3.039 | 3.59839 | 3.74718 |
Amortization | 0.49649 | 0.52042 | 0.54708 | 1.06629 | 1.24958 |
Deferred Taxes | 0 | 0 | 0.0054 | 0 | |
非现金物品 | 39.6153 | 34.0382 | 56.9816 | 21.5747 | 13.3131 |
营运资金的变化 | 19.8342 | 50.3515 | -71.0718 | -3.54312 | 5.10778 |
投资活动产生的现金 | 109.586 | -175.344 | -58.7957 | -9.045 | 42.4199 |
资本支出 | -0.96915 | -1.23101 | -1.52067 | -0.98793 | -2.08502 |
其他投资现金流量项目,总计 | 110.555 | -174.113 | -57.2751 | -8.05707 | 44.5049 |
融资活动产生的现金 | 81.8407 | 211.499 | 465.28 | 105.398 | 31.0373 |
融资现金流项目 | 0 | 0 | 2.37997 | -0.35463 | 0 |
股票的发行(报废),净额 | 81.8407 | 211.499 | 462.728 | 8.3086 | 31.0373 |
外汇效应 | -0.02556 | -0.03013 | 0.02721 | ||
现金净变化 | -24.8144 | -179.584 | 228.532 | -1.49754 | -0.09295 |
已付现金利息 | 1.06698 | 1.0778 | 4.62476 | 2.71759 | |
债务的发行(退还),净额 | 0 | 0 | 0.17162 | 97.4436 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -40.6493 | -279.818 | -225.355 | -187.571 | -79.0737 |
Cash From Operating Activities | -36.6645 | -216.215 | -179.875 | -112.41 | -61.8821 |
Cash From Operating Activities | 0.70738 | 3.65671 | 2.77667 | 1.86996 | 0.92938 |
Amortization | 0.08208 | 0.49649 | 0.37691 | 0.25733 | 0.12677 |
Non-Cash Items | 1.7177 | 39.6153 | 35.4049 | 29.4844 | 15.7913 |
Cash Interest Paid | 0.53349 | 1.06698 | 1.06698 | 0.53349 | 0.53349 |
Changes in Working Capital | 1.47767 | 19.8342 | 6.92106 | 43.5492 | 0.3442 |
Cash From Investing Activities | 18.9999 | 109.586 | 55.585 | 11.0283 | 21.3323 |
Capital Expenditures | -0.29698 | -0.96915 | -0.80404 | -0.71721 | 0 |
Other Investing Cash Flow Items, Total | 19.2969 | 110.555 | 56.3891 | 11.7456 | 21.3323 |
Cash From Financing Activities | -0.4247 | 81.8407 | 75.1727 | 71.3612 | 28.422 |
Financing Cash Flow Items | 0 | ||||
Issuance (Retirement) of Stock, Net | -0.4247 | 81.8407 | 75.1727 | 71.3612 | 28.422 |
Foreign Exchange Effects | -0.00192 | -0.02556 | -0.0379 | -0.02134 | -0.00656 |
Net Change in Cash | -18.0912 | -24.8144 | -49.1555 | -30.0419 | -12.1343 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Deferred Taxes |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Inovio Pharmaceuticals Company profile
关于 Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc.(INOVIO)是一家生物技术公司。 公司致力于将设计好的脱氧核糖核酸(DNA)药物和疫苗推向市场,以帮助人们预防传染病,包括COVID-19,并帮助治疗癌症患者和与人乳头瘤病毒(HPV)有关的疾病。 其DNA药物管道包括三种类型的候选产品,即预防性DNA疫苗、治疗性DNA免疫疗法和DNA编码的单克隆和双特异性抗体(dMAbs和dBTAs),这些产品利用INOVIO的综合平台的两个组成部分SynCon和CELLECTRA。 公司的SynCon技术创造了优化的质粒。 INOVIO的CELLECTRA智能递送装置促进了其DNA药物在细胞中的摄取。 其SynCon DNA药物旨在产生抗原特异性抗体和T细胞反应。
Industry: | Biotechnology & Medical Research (NEC) |
6769 Mesa Ridge Rd.
SAN DIEGO
CALIFORNIA 92121
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球580,000万多名交易者的一份子,选择利用Capital.com进行交易吧。